Walleye Trading’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q3
Sell
-21,000
Closed -$1.17M 4514
2019
Q2
$1.17M Sell
21,000
-4,700
-18% -$245K 0.01% 1459
2019
Q1
$1.3M Buy
25,700
+20,300
+376% +$903K 0.01% 1427
2018
Q4
$218K Sell
5,400
-31,200
-85% -$1.61M ﹤0.01% 3317
2018
Q3
$2.54M Buy
36,600
+4,500
+14% +$341K 0.01% 1113
2018
Q2
$2.43M Buy
32,100
+26,400
+463% +$1.66M 0.01% 1159
2018
Q1
$300K Sell
5,700
-3,200
-36% -$186K ﹤0.01% 3134
2017
Q4
$475 Buy
8,900
+2,000
+29% +$111K ﹤0.01% 2649
2017
Q3
$412 Buy
+6,900
New +$417K ﹤0.01% 2654

Other funds holding EGRX

Walleye Trading's EGRX Position: Q1 2020 in Review

Walleye Trading sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2020, closing a stake of 360 shares — an estimated $22K sold.

Walleye Trading first reported a position in EGRX in Q2 2015 and held it in 12 quarters. The position peaked at $433K in Q3 2018. 168 funds tracked by Wall St. Rank hold EGRX as of Q1 2020.

  • Walleye Trading reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
  • Walleye Trading sold 360 Eagle Pharmaceuticals, Inc. shares in Q1 2020, an estimated $22K.
  • Walleye Trading first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2015 and held it in 12 quarters.
  • Walleye Trading's Eagle Pharmaceuticals, Inc. position peaked at $433K in Q3 2018.
  • 168 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2020.

Based on Walleye Trading's 13F filing for Q1 2020, filed 15 May 2020.